Subscribe To

Price Alert Latest News Economic Calendar News

SNPX / Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present a "Spotlight Showcase" of Synaptogenix under the title "Regenerative Therapeutics" on Tuesday, March 22nd at 8am ET. "Recently reported consolidated results of Synaptogenix Phase 2 clinical trial patients showed significant, persistent improvement of the cognitive psychometric Severe Impairment Battery (SIB) scores, over baseline, in a placebo-controlled publication on Bryostatin for advanced AD patients (Thompson, Tuchman, and Alkon, Journal Alzheimer's disease). Read More

Demo Live Account See Partner Details

Content Topics

Synaptogenix

Present

Sachs

Annual

Neuroscience

Innovation

Stock

SNPX

Posted: Mar 22 2022, 09:15

Author Name: PRNewsWire

SNPX News

By InvestorPlace
December 16, 2022

Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?

Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the

By Seeking Alpha
December 9, 2022

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work

By PRNewsWire
March 29, 2022

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company

By PRNewsWire
March 22, 2022

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company

By PRNewsWire
March 15, 2022

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutic

By Seeking Alpha
November 16, 2021

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p

By Seeking Alpha
November 16, 2021

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p

By Seeking Alpha
November 16, 2021

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe p

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

SNPX / Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix

Present

Sachs

Annual

Neuroscience

Innovation

Stock

SNPX

SNPX News

Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment